Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor

被引:0
|
作者
B Foveau
C Leroy
F Ancot
J Deheuninck
Z Ji
V Fafeur
D Tulasne
机构
[1] CNRS UMR 8161,
[2] Institut de Biologie de Lille,undefined
[3] CNRS-Institut Pasteur de Lille-Université de Lille 1-Université de Lille 2,undefined
来源
关键词
c-MET; tyrosine kinase receptor; hepatocyte growth factor; apoptosis; caspase;
D O I
暂无
中图分类号
学科分类号
摘要
Activation of the MET tyrosine kinase receptor by hepatocyte growth factor/scatter factor is classically associated with cell survival. Nonetheless, stress stimuli can lead to a caspase-dependent cleavage of MET within its juxtamembrane region, which generate a proapoptotic 40 kDa fragment (p40 MET). We report here that p40 MET is in fact generated through an additional caspase cleavage of MET within its extreme C-terminal region, which removes only few amino acids. We evidenced a hierarchical organization of these cleavages, with the C-terminal cleavage favoring the juxtamembrane one. As a functional consequence, the removal of the last amino acids of p40 MET increases its apoptotic capacity. Finally, cells expressing a MET receptor mutated at the C-terminal caspase site are unable to generate p40 MET and are resistant to apoptosis, indicating that generation of p40 MET amplifies apoptosis. These results revealed a two-step caspase cleavage of MET resulting in the reshaping of this survival receptor to a proapoptotic factor.
引用
收藏
页码:752 / 764
页数:12
相关论文
共 50 条
  • [31] How to make tubes:: signaling by the Met receptor tyrosine kinase
    Rosário, M
    Birchmeier, W
    TRENDS IN CELL BIOLOGY, 2003, 13 (06) : 328 - 335
  • [32] Met receptor tyrosine kinase cross-talk in tumorigenesis
    Lai, Andrea
    Park, Morag
    CANCER RESEARCH, 2011, 71
  • [33] A NOVEL PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE OF THE MET FAMILY
    RONSIN, C
    MUSCATELLI, F
    MATTEI, MG
    BREATHNACH, R
    ONCOGENE, 1993, 8 (05) : 1195 - 1202
  • [34] Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
    Danilkovitch-Miagkova, A
    Zbar, B
    JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (07): : 863 - 867
  • [35] Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor
    Jeffers, M
    Koochekpour, S
    Fiscella, M
    Sathyanarayana, BK
    Vande Woude, GF
    ONCOGENE, 1998, 17 (21) : 2691 - 2700
  • [36] DIMERIZATION MEDIATED THROUGH A LEUCINE-ZIPPER ACTIVATES THE ONCOGENIC POTENTIAL OF THE MET RECEPTOR TYROSINE KINASE
    RODRIGUES, GA
    PARK, M
    MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (11) : 6711 - 6722
  • [37] Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
    Snuderl, Matija
    Fazlollahi, Ladan
    Le, Long P.
    Nitta, Mai
    Zhelyazkova, Boryana H.
    Davidson, Christian J.
    Akhavanfard, Sara
    Cahil, Daniel P.
    Aldape, Kenneth D.
    Betensky, Rebecca A.
    Louis, David N.
    Iafrate, A. John
    CANCER CELL, 2011, 20 (06) : 810 - 817
  • [38] Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation
    Leiser, Dominic
    Pochon, Benoit
    Blank-Liss, Wieslawa
    Francica, Paola
    Glueck, Astrid A.
    Aebersold, Daniel M.
    Zimmer, Yitzhak
    Medova, Michaela
    FEBS LETTERS, 2014, 588 (05): : 653 - 658
  • [39] MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    Kubo, Takafumi
    Yamamoto, Hiromasa
    Lockwood, William W.
    Valencia, Ilse
    Sob, Junichi
    Peyton, Michael
    Jida, Masaru
    Otani, Hiroki
    Fujii, Tetsuva
    Ouchida, Mamoru
    Takigawa, Nagio
    Kiura, Katsuyuki
    Shimizu, Kenji
    Date, Hiroshi
    Minna, John D.
    Varella-Garcia, Marileila
    Lam, Wan L.
    Gazdar, Adi F.
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) : 1778 - 1784
  • [40] AUTOPHOSPHORYLATION MODULATES THE KINASE-ACTIVITY AND ONCOGENIC POTENTIAL OF THE MET RECEPTOR TYROSINE KINASE
    RODRIGUES, GA
    PARK, M
    ONCOGENE, 1994, 9 (07) : 2019 - 2027